PEGylation is a modification commonly used to increase the half-life of therapeutic proteins. The strategy for immunogenicity testing of these compounds should include methods to detect both anti-protein and anti-PEG antibodies. We previously reported a method for the detection of anti-PEG antibodies using ProterixBio's (formerly BioScale) acoustic membrane microparticle (AMMP) technology. Our initial method development work showed the assay was capable of detecting antibodies in human serum with a sensitivity of 1 μg/mL with good reproducibility (CV < 7%). Since the publication of this initial paper, additional experimentation was performed in an effort to validate the assay for support of clinical sample analysis. This additional data indicate that the method has high variability (CV% > 20) and is unsuitable to support clinical sample analysis.

Download full-text PDF

Source
http://dx.doi.org/10.1208/s12248-018-0228-3DOI Listing

Publication Analysis

Top Keywords

proterixbio's bioscale
8
anti-peg antibodies
8
generic anti-peg
4
anti-peg antibody
4
antibody assay
4
assay proterixbio's
4
bioscale vibe
4
vibe platform
4
platform poor
4
poor reproducibility
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!